SEC Form 4 · accession 0001179110-17-004353
Allergan plc · AGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James DArecca
Officer — CHIEF ACCOUNTING OFFICER
Period of report
Mar 7, 2017
Accepted (ET)
Mar 9, 2017 · 5:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001578845
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, par value $0.0001F1,F2 | Mar 7, 2017 | A | 1,085 | $239.60 | A | 3,600 | D | |
| Ordinary Shares, par value $0.0001F2 | Mar 8, 2017 | F | 77 | $239.44 | D | 3,523 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported securities are restricted share units, each of which represents a right to receive one ordinary share of Allergan plc. The restricted share units will vest twenty-five percent (25%) on March 7, 2018, twenty-five percent (25%) on March 7, 2019, twenty-five percent (25%) on March 7, 2020 and twenty-five percent (25%) on March 7, 2021.
- F2Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.